BMS, AstraZeneca’s Onglyza Enters Murky Regulatory Waters

Scrutiny of potential cardiovascular risks looms over new diabetes drugs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet